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Abstract. The leveraged use of biomarkers presents an opportunity in understanding target engagement
and disease impact while accelerating drug development. For effective integration in drug development,
it is essential for biomarkers to aid in the elucidation of mechanisms of action and disease progression.
The recent years have witnessed signiﬁcant progress in biomarker selection, validation, and qualiﬁcation,
while enabling surrogate and clinical endpoint qualiﬁcation and application. Biomarkers play a central
role in target validation for novel mechanisms. They also play a central role in the learning/conﬁrming
paradigm, particularly when utilized in concert with pharmacokinetic/pharmacodynamic modeling.
Clearly, these attributes make biomarker integration attractive for scientiﬁc and regulatory applications
to new drug development. In this review, applications of proximal, or target engagement, and distal, or
disease-related, biomarkers are highlighted using the example of the recent development of sitagliptin for
type 2 diabetes, wherein elucidation of target engagement and disease-related biomarkers signiﬁcantly
accelerated sitagliptin drug development. Importantly, use of biomarkers as tools facilitated design of
clinical efﬁcacy trials while streamlining dose focus and optimization, the net impact of which reduced
overall cycle time to ﬁling as compared to the industry average.
KEY WORDS: disease progression; distal biomarkers; DPP4; glucose; proximal biomarkers; sitagliptin;
type 2 diabetes.
INTRODUCTION
Drug development attrition and the declining number of
new chemical entities have been subjects of major scientiﬁc
and legislative debate (1–6). Importantly, this debate has
called into question the productiveness and effectiveness of
traditional drug development given the limited probabilities
of success of any new chemical entity. Notably, two regulatory
initiatives one in the United States, and one in the European
Union have addressed the so-called ‘pipeline problem’, and
these include the Food and Drug Administration (FDA)
critical path to new medicines initiative in the US (7) and the
European Technology Platform for Innovative Medicines in
the Europe (8). These initiatives were launched to enhance
and accelerate the development of new chemical entities, as
well as to insure the rapid application of scientiﬁc break-
throughs to approval and use. Both of these worldwide
initiatives emphasize the application of biomarkers and
disease progression modeling as a centerpiece to effective
drug development.
A particularly worrisome statistic in new drug develop-
ment is that only ~11% of all new mechanisms are pharma-
cologically viable (1) and enter clinical development,
highlighting the need for efﬁcient use of biomarkers in
translational medicine. To mitigate this issue, a number of
initiatives have been developed to insure the effective
integration of biomarkers in early drug development. These
have included the FDA/National Institutes of Health (NIH)
Consensus Conference of 1999 (9,10), the biomarker consor-
tium in 2006 (9,10), and several efforts within Pharmaceutical
Research and Manufacturers of America (PhRMA), FDA,
NIH, and professional scientiﬁc organizations such as Amer-
ican Association of Pharmaceutical Scientists, American
College of Clinical Pharmacology, and American Society for
Clinical Pharmacology and Therapeutics. Declining number
of new chemical entities, late stage attrition due to safety and
efﬁcacy, and suboptimal risk/beneﬁt of marketed drugs all
have prompted an increasing attention to the utility of
biomarkers (1).
The discipline of experimental medicine engages in
clinical research with a focus on biomarkers, the development
of experimental models, and clinical target validation in
support of drug development programs (2,9,10). Speciﬁcally,
research is designed to provide an early and often preliminary
assessment of beneﬁcial pharmacologic activity or efﬁcacy,
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in order to facilitate decision making. These approaches have
the potential to provide a bridge from results in preclinical
models to clinical results. This may provide an early read on
pharmacodynamics and the pharmacokinetic-pharmacodynamic
relationship. The use of experimental medicine has a clear
charter: increase efﬁciency of drug development process by
providing neededinformationonmechanismsofaction,dose-
response, early reads of efﬁcacy and safety, thereby improv-
ing the quality and speed of decision-making (de-prioritize
failures and accelerate winners). In some settings, experi-
mental medicine may aid in regulatory evaluation and
approval.
While experimental medicine leverages a range of tools
that include biomarkers, imaging, molecular proﬁling and
pharmacogenomic approaches, the focus of the present
review is on markers for target engagement (i.e., proximal
markers or how robustly a drug interacts with the mecha-
nism) and disease (i.e. distal markers or indicators of drug
efﬁcacy). Further, while biomarkers reﬂect both safety and
efﬁcacy attributes, the focus of the present article is on
markers related to efﬁcacy.
There are consensus guidelines on the deﬁnitions and
nomenclature of biomarkers and these have been outlined by
the Biomarkers Deﬁnitions Working Group and is summa-
rized in a publication (11). This review focuses on biomarkers
which include measurements that suggest the etiology of, the
susceptibility to, or the progress of disease; measurements
related to the mechanism of response to treatments; and
measurements linked to established clinical endpoints in
response to therapeutic interventions. In this review, applica-
tions of distal and proximal biomarkers to assess pharmaco-
logical activity are presented. Some distal biomarkers have
been clearly demonstrated to reﬂect therapeutic response,
and others less clearly validated. Proximal biomarkers reﬂect
the drug mode of action, but do not necessarily have an
established or direct relationship to therapeutic response;
examples include markers of enzyme inhibition or receptor
binding. When such proximal biomarkers have a close,
validated relationship to therapeutic response, efﬁcacy infor-
mation can be derived from extent of change in the
biomarker, but such information must generally be viewed
cautiously, as the tight relationship between extent of change
in a proximal biomarker and impact on a distal biomarker in
one model may not necessarily apply in other settings.
Regulatory guidance indicates that a distal biomarker is
not considered an acceptable surrogate endpoint for ascer-
taining efﬁcacy of a new drug unless it has been demonstrated
to function as a valid indicator of clinical beneﬁt( i.e., is a
valid surrogate). Examining the relationship between drug
concentration and the change in a biomarker as a function of
time using exposure/response relationships can provide
important and useful information. Such PK/PD relationships
aid in the development of clinical trial designs, thereby
accelerating drug development.
The area of biomarker qualiﬁcation has been discussed
in a recent review (9,10). Brieﬂy, qualiﬁcation is the process
of establishing the link between a biomarker and the clinical/
therapeutic endpoints that the biomarker is intended to
relate. A ﬁt-for-purpose biomarker qualiﬁcation is a graded
evidentiary process linking a biomarker with biology and
clinical endpoints and dependent on the intended application.
Ideally, biomarker development needs to initiate as early
as possible in drug discovery and development. The biomark-
er strategy and concomitant exposure/response strategy needs
to be initiated as early as a novel mechanism or scientiﬁcally
qualiﬁed target is identiﬁed.
Biomarkers and pharmacodynamic models can aid in
making decisions about moving a compound forward in devel-
opment, guiding early clinical development strategy. In the
sitagliptin type 2 diabetes development program, plasma
dipeptidyl-peptidase IV (DPP4) activity was implemented as
a proximal or target engagement biomarker. Evidence of
target engagement at a well tolerated dose will enhance the
level of conﬁdence that a given dose/concentration is adequate
for proof-of-concept purposes and potentially allow decisions
made about a compound to be generalized to the target. In the
sitagliptin program, measures of serum glucose, insulin
(reﬂecting β cell response), glucagon (reﬂecting α cell
response),etcwereusedasdistalordiseaserelatedbiomarkers
since they are intimately linked to clinical outcomes.
For a biomarker to aid in decision making, it is imperative
that there is a deﬁned relationship (preferably quantitative)
between a target engagement promixal marker and a disease
related distal biomarker (Fig. 1). If such links are established,
then the opportunities to engage biomarkers as decision
making tools are greatly enhanced. Speciﬁcally, the interplay
between proximal target engagement biomarkers and distal
disease related biomarkers may aid in a better understanding
of the likelihood of success a new mechanism of disease might
have, and as such an inference on proof-of-concept can be
made. A positive proof-of-concept can be considered achieved
if both target engagement and disease related biomarkers are
positive, whereas when both target engagement and disease
related biomarkers are negative, it may suggest that the
mechanism may not have been tested to its potential. On the
other hand, if target engagement biomarker is positive and
there were no associated effect on disease related biomarker,
then an inference that proof-of-concept has not been attained
(or that the probability of doing so is low) with either the
compound and the mechanism could be drawn. Inherent in
such assessments is the quantitative modeling of proximal and
distal measures to support proof-of-concept as well as role of
the systems biology in quantitative ﬁngerprinting of disease
pathways. The greater the uncertainty in a new mechanism, the
lower the conﬁdence there is in terminating compounds or
arresting development necessary to achieve quick-kill and
redirecting resources.
In this review, the speciﬁc aspects of the important
interplay of proximal and distal biomarkers are highlighted
Fig. 1. An idealized model for biomarkers, illustrating proximal or
target engagement and distal or disease-related attributes
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how biomarkers can accelerate early clinical development
and streamline late development time to ﬁling.
CASE STUDY: SITAGLIPTIN, A NOVEL
DPP4 INHIBITOR
Background on Type 2 Diabetes—Epidemiology
and Pathophysiology
The worldwide prevalence of type 2 diabetes is growing
by 3% per annum, and 90% of all patients with diabetes have
type 2 (previously referred to as adult-onset) diabetes (12,13).
Underlying this marked increase in prevalence are sedentary
lifestyles and the consumption of diets rich in saturated fat
and calories leading to higher prevalence of obesity. Obesity,
especially central or visceral obesity, leads to insulin resis-
tance, a key underlying factor in the pathogenesis of T2D
(14).
There are three key pathogenic defects contributing to
hyperglycemia in patients with T2D which are generally
present in all populations, albeit the extent that each may
contribute can differ between individuals and across popula-
tions. These defects include insulin resistance, loss of insulin
secretion, and hepatic glucose overproduction (15). Insulin
resistance is characterized by a decrease in the ability of
insulin to stimulate tissue glucose uptake and utilization, and
represents an early defect in patients who ultimately develop
T2D. To counter insulin resistance, the pancreatic β-cell
increases the release of insulin both in fasting and post-meal
states. This maintains euglycemia (normal glucose levels) but
leads to a stress on the β-cell. In patients destined to develop
T2D, β-cell compensation begins to fail, insulin secretion
diminishes, and decompensation leads to frank hyperglycemia—
and onset of diabetes. Thus, the loss of β-cell function
reﬂected by a decrease in insulin secretion underlies the
progression from normal glucose tolerance to impaired
glucose tolerance and then to frank diabetes (16,17). This
reduction in β-cell function is thought to occur both because
of the loss of pancreatic islet β-cell mass (18) and because of
the loss of glucose-stimulated insulin secretion. Not only
does the deterioration of β-cell function lead to the onset of
diabetes, continued deterioration after the onset of diabetes
underlies the need for progressively more treatments. Initially
patients may respond to monotherapy but most patients
require combination therapy, and eventually parenteral
insulin therapy.
A third pathogenetic defect in patients with T2D is
hepatic glucose overproduction. This defect correlates with
the rise in fasting plasma glucose levels, and in part reﬂects
inappropriate elevations in glucagon due to excessive
pancreatic islet α-cell glucagon release. Glucagon is a key
glucoregulatory hormone that stimulates liver glucose
production. In non-diabetic individuals, glucagon rises in
the fasting state helping to maintain glucose production and
normal glucose levels, and is suppressed after a meal (with
a carbohydrate load) thereby helping to avoid a marked
rise in post-meal glucose concentrations. In patients with
T2D, fasting glucagon levels are elevated, and glucagon
levels are inadequately suppressed—or paradoxically in-
creased—after a meal. These alterations in glucagon lead to
higher fasting and post-meal hepatic glucose production,
contributing to hyperglycemia (19).
The Incretin Axis and DPP-4 Inhibition
The mechanisms underlying the loss in pancreatic β-cell
function with progression to T2D and subsequent worsening
of diabetes remain poorly understood. However, defects in
the incretin hormones—gut-derived peptides that stimulate
insulin secretion—have been recognized and may contribute
to diminished β-cell function. Incretins are released into the
circulation after consumption of a meal. Glucagon-Like
Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic
Peptide (GIP) account for the majority of the incretin
response. Incretins increase insulin gene expression, insulin
biosynthesis and insulin release in a glucose-dependent
manner—that is, these effects only occur with normal or
elevated glucose levels, but are not seen when glucose levels
fall below normal levels. Impairments in the incretin
hormones have been observed in patients with T2D, and
even in patients with pre-diabetic conditions. These defects
include a decrease in GLP-1 concentrations—with a relatively
normal response to GLP-1, and normal GIP levels—with
diminished response to GIP (20,21). GLP-1 and glucose-
dependent insulinotropic release was signiﬁcantly reduced,
but infusion of GLP-1 appropriately stimulated insulin
secretion (20). A reduced response to GIP infusion was also
observed (21). Since GLP-1 signaling is intact in patients with
T2D, agents that mimic the effect of GLP-1 (GLP-1 analogs)
have been developed. GLP-1 itself is difﬁcult to use clinically
given the very short half life in the systemic circulation. An
early proof-of-concept was shown with subcutaneously
administered GLP-1 in patients with T2D; a sub-chronic
(6-week) continuous infusion resulted in clinically signiﬁ-
cant decreases in fasting plasma glucose (14.1 to 10.1 mM)
and HbA1c (from 9.2 to 7.9%) as compared to placebo (22).
To avoid the need for continuous subcutaneous infusion,
analogs with extended half-lives (because they are more
resistant to metabolism by the enzyme DPP4) have been
developed. Exenatide (Byetta™) is now approved for
patients with T2D and liraglutide (NN2211) is in late stage
development (23,24). Both agents are subcutaneously admin-
istered and have been shown to improve glycemic control by
reducing fasting and postprandial glucose concentrations via
glucose-dependent insulin secretion, restoring ﬁrst-phase
insulin response, and β-cell responsiveness to glucose (25,
26). In addition, GLP-1 receptor agonists suppress glucagon
secretion, delay gastric emptying, and reduce food intake
(25).
A second strategy targeting the incretin axis is the
pharmacological inhibition of the enzyme DPP4, as illustrated
in Fig. 2. Both GLP-1 and GIP are rapidly inactivated by the
DPP-4; therefore, inhibition of DPP-4 stabilizes and thereby
increases the concentration of the active forms of these
incretins.
Pharmacology of DPP4 Inhibition
Dipeptidyl peptidase-IV (DPP4) inhibitors represent a
new therapeutic approach to the treatment of type 2 diabetes
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class in development, sitagliptin (Merck & Co., Inc.) is the
ﬁrst approved by the US FDA. Late stage development
compounds include vildagliptin (Novartis, Inc) and saxaglip-
tin (Bristol-Myers Squibb, Inc.).
Sitagliptin is an orally active, potent, and selective DPP4
inhibitor that targets the incretin axis in the treatment of
patients with T2D (29). This pharmacological approach has
been supported by data obtained with DPP4 deﬁcient mice
(30), and in studies using DPP4 inhibitors in humans (31–38).
For example, mice that are bred to be genetically deﬁcient in
DPP4 demonstrate improved glucose tolerance, with approx-
imately threefold elevated active GLP-1 levels, increased
insulin secretion, and decreased circulating glucagon (30).
Selective inhibitors of DPP-4, such as sitagliptin, have shown
minimal toxicities in animal safety studies – however agents
that are not as selective, inhibiting both DPP-4 and other
related proteases such as DPP-8/9, have been shown to
exhibit signiﬁcant preclinical toxicities (39). In clinical studies
of patients with T2D treated with sitagliptin, sustained DPP4
inhibition has been observed, leading to increased active
GLP-1 and GIP levels, decreased post-glucose load glucose
excursion, increased insulin and C-peptide levels, and de-
creased glucagon concentrations (33, 36–38). Glucose lower-
ing with DPP4 inhibition occurs via increased insulin release
and reduced glucagon levels (31,40,41).
A DPP4 inhibitor, such as sitagliptin, may also have
several advantages over currently available insulin secreta-
gogues such as sulfonylurea (SU) agents; these include a
neutral effect on body weight (vs weight gain with an SU
agent) and an incidence of hypoglycemia that is generally
similar to placebo (vs an higher rate of hypoglycemia with an
SU) (42). This effect appears to be consistent with the
observation that GLP-1 stimulates insulin secretion in a
glucose-dependent manner (43).
A potential advantage of DPP4 inhibitors is based on
possible trophic effects of GLP-1 and other incretins on
pancreatic beta-cells. DPP4 inhibitors have been shown to
improve pancreatic β-cell function and mass in chronic rodent
models of diabetes (44,45) and in patients with T2D (46,47).
However, only with long-term clinical studies will it be
understood if this beneﬁcial effect in animal models translates
to a beneﬁt in patients with T2D.
The following sections highlight the prospective use of
biomarkers in early clinical development for sitagliptin.
Speciﬁcally, the sections highlight application of target
engagement or proximal biomarkers such as DPP4 enzyme
activity and active GLP-1 and GIP levels, as well as those that
are more distal or disease-based, such as insulin, c-peptide,
glucose, and glucagon. Importantly, integration of these
biomarkers occurred in the ﬁrst-in-human study in healthy
normoglycemic volunteers as well as subsequent studies in
patients with T2D and obese patients.
Application of Biomarkers in Sitagliptin’s Early Clinical
Development Strategy
Preclinical Studies and Translational Research
An extensive preclinical investigation with sitagliptin
provided an effective guidance for translational development.
During preclinical development, it was critical to assess the
degree of DPP4 inhibition that is likely to elicit sustained and
clinically meaningful pharmacodynamic effects in humans.
Studies in mice examined the decrease in the blood glucose
proﬁle (AUC) after a glucose load with a range of doses of
sitagliptin. Sitagliptin decreased the glucose AUC in a dose-
dependent manner achieving maximum efﬁcacy at 1 mg/kg
(which approximated to 46% inhibition) (29). Experiments
included measurements of plasma DPP4 inhibition, active
GLP-1, and drug concentrations. Maximal efﬁcacy was
found to approximately correspond to plasma DPP4 inhibi-
tion >80% (note that assay values did not correct for dilution
and that in vivo values are higher) and to plasma concen-
trations ≥100 nM, which resulted in a two- to threefold
increase in active GLP-1, analogous to that observed upon
glucose challenge in DPP4 deﬁcient mice (Nancy Thornberry,
data on ﬁle). This enabled the selection of primary endpoints
in clinical studies with healthy subjects and patients with T2D
including plasma pharmacokinetics of sitagliptin, plasma DPP4
enzyme activity, and levels of active GLP-1 fasting and
following a meal or glucose challenge. A Clinical Development
Lab (CDL) played an integral role in developing validated
assays for active GLP-1 and plasma DPP4 inhibition in human
samples, streamlining the transfer of the assays from basic
(preclinical) research to clinical research.
To provide direct evidence of the pharmacologic effects
of sitagliptin in type 2 diabetics, a single-dose study examining
reductions in glucose post-OGTT/meal challenge was per-
formed immediately following completion of the single-dose
healthy volunteer studies.
Early Clinical Development—Single Dose Clinical Studies
The early development program for sitagliptin had two
objectives: ﬁrst to conﬁrm proof-of-concept for sitagliptin,
and second, to provide dose focus information for later stage
drug development. Proof-of-concept, as deﬁned earlier in the
manuscript, was to achieve positive target engagement of the
proximal biomarkers (exempliﬁed here as DPP4 activity and
active GLP-1 augmentation) and disease related disease
biomarker (such as blood glucose) responses. If this were to
be met and dose/response adequately delineated, then
acceleration of the development program could be achieved.
A central premise behind this objective was that the
pharmacodynamic proﬁle (DPP-4 inhibition, GLP-1 stabiliza-
tion) observed after acute dosing would be predictive of
Fig. 2. Target engagement (DPP4, GLP) and distal (insulin, glucose,
glucagon) biomarkers for glucose control via the DPP4 pathway
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plasma DPP4 activity was incorporated in the ﬁrst human
study for sitagliptin in normoglycemic healthy subjects (33).
Sitagliptin demonstrated marked inhibition of plasma DPP4
activity in a dose dependent manner (Fig. 3)( 33). Speciﬁcally,
sitagliptin at doses of 100 mg or higher produced ~80%
inhibition over 24 h. Analysis of the pharmacokinetic-
pharmacodynamic relationship between plasma sitagliptin
concentration and inhibition of plasma DPP4 activity further
revealed that inhibition of plasma DPP4 activity of 80% or
greater occurred when sitagliptin plasma concentrations were
at least 100 nM (33). It was later discerned that the extent of
inhibition of DPP4 activity in vivo would be higher (e.g., 80%
inhibition in this assay would be estimated to represent more
than 95% inhibition in vivo if the Michaelis-Menton equation
is applied) since no dilution corrections during assay proce-
dures had been employed (33). These initial data were used
to predict dosing regimens for patients with T2D, based on
the assumption that DPP-4 inhibition in animal models that
maximally lowered glucose levels would also provide effective
glucose lowering in the clinical setting in diabetic patients.
Based on studies in healthy subjects, this predicted that a
dose of 100-mg or higher once-daily would be associated with
near-maximal glucose lowering.
Several doses of sitagliptin produced postmeal increases
in GLP-1 that were approximately two to threefold higher
than corresponding values for placebo. This increase is also
consistent with near maximal acute glucose lowering efﬁcacy
in preclinical studies (Nancy Thornberry, data on ﬁle).
Inhibition of sitagliptin further appeared to increase incretin
levels by stabilizing the active form of GLP-1 rather than
increasing secretion, this hypothesis being supported by the
ﬁnding that sitagliptin increased post meal active GLP-1
levels as well as the ratio of active to total GLP-1 levels but
had no impact on total GLP-1 levels. There was no clinically
meaningful effect of sitagliptin on fasting and postmeal levels
of glucose, insulin, glucagon, and C-peptide, an expected
ﬁnding for healthy normoglycemic subjects. The observation
that increase in GLP-1 and GIP with sitagliptin in healthy
subjects did not lead to hypoglycemia was an important one.
This supported the glucose-dependency of insulin secretion,
reviewed above. Presumably, in normal individuals the
increase in active incretin levels with sitagliptin that enhances
insulin release likely leads to an initial very small decrease in
glucose—and as soon as glucose levels fall below normal, no
further insulin release occurs. In normal subjects, no mean-
ingful reduction in glucose concentrations—and no episodes
of hypoglycemia—are observed. In contrast, as reviewed
above, in patients with diabetes who have elevated glucose
levels, sitagliptin increases active GLP-1 levels, leading to
insulin release and lowering of glucose from elevated
concentrations to more normal concentrations. These data
supported the continued clinical development of sitagliptin, as
assessed by safety, pharmacokinetics, and pharmacodynamics.
Importantly, these data from single dose studies conﬁrmed
the observations in preclinical models of diabetes that DPP-4
inhibition increased active incretin levels and improved
glucose concentrations, with maximum response at >80%
DPP-4 inhibition.
Understanding the dynamic aspects of how DPP4
inhibition modulated incretin response was crucial in facili-
tating drug development acceleration. Since both GLP-1 and
GIP are released in response to a meal and help achieve
glycemic control, the degree to which DPP-4 inhibition could
inﬂuence the level of active incretin augmentation necessary
for glucose lowering efﬁcacy after an oral glucose tolerance
test (OGTT) could be assessed after single doses. Sitagliptin
reduced glycemic excursion following a glucose challenge in
patients with T2D (Fig. 4)( 37). Sitagliptin also dose
dependently inhibited plasma DPP4 activity which correlated
well with the two time points of OGTT, wherein a more dose
related separation was evident (37). Sitagliptin signiﬁcantly
enhanced post-OGTT levels of active GLP-1 and GIP levels
as well as the ratio of active to total GLP-1 and active to total
GIP levels. Total GLP-1 and GIP levels were slightly reduced
by about 11 to 20% after an OGTT following treatment with
sitagliptin as compared to placebo (37). Sitagliptin signiﬁ-
cantly increased post-glucose challenge insulin and C-peptide
levels, and reduced post-glucose challenge glucagon levels
Fig. 3. Time course of inhibition of plasma DPP4 activity after
administration of placebo (open circles) or single oral doses of
sitagliptin—1.5 (solid circles), 12.5 (open squares), 50 (solid squares),
and 200 (open triangles) mg (A) and 5 (solid circles), 25 (fed [solid
squares] and fasted [open squares]), and 100 (open triangles) mg (B)
to healthy, young male subjects. [Reprinted with permission from
Macmillan Publishers Ltd: Clinical Pharmacology and Therapeutics
(78(6), copyright Dec 2005]
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to be roughly associated with plasma sitagliptin concentra-
tions of approximately 100 nM or greater, inhibition of
plasma DPP4 activity of approximately 80% or greater and
approximately 2-fold or greater enhancement of active GLP-1
and GIP levels. Exploratory Emax models, assessing the
relationship between sitagliptin plasma concentrations and
the reduction of postchallenge glucose as well as with
increases in active GLP-1 and GIP levels, further supported
that estimated EC75 values (i.e., 75% of a maximal effect,
assuming a near maximal response) for sitagliptin plasma
concentrations of approximately 100 nM may be necessary
for efﬁcacy.
Early Clinical Development—Multiple Dose Studies
Both proximal and distal biomarkers of DPP4 pathway
were incorporated in a multiple dose study in healthy
normoglycemic subjects (38). Sitagliptin produced dose- and
concentration-dependent inhibition of plasma DPP4 activity
(38), the level of inhibition being consistent those observed in
prior clinical studies and in pre-clinical rodent models (see
Section on translational research above). The relationship
between sitagliptin plasma concentrations and inhibition of
plasma DPP-4 activity was not altered after multiple doses,
given no substantial differences in EC50 values.
Sitagliptin, at doses of 25-mg and higher demonstrated
post-meal increases in active GLP-1 levels (vs. placebo) of
approximately two- threefold or higher, a value that correlat-
ed with near maximal acute glucose lowering efﬁcacy in pre-
clinical rodent models (Fig. 5). The ratio of active to total
post-meal GLP-1 levels generally increased approximately
two- to threefold following sitagliptin treatment, as compared
to placebo and an obvious dose response beyond this level of
stabilization was not evident. DPP4 inhibition by sitagliptin
appears to enhance incretin levels by stabilizing the active
form of GLP-1 rather than stimulating incretin secretion,
since sitaglitpin increases post-meal active GLP-1 levels as
well as the ratio of active to total GLP-1 levels, but does not
appear to increase levels of total GLP-1.
Fig. 4. Plasma glucose (a), serum insulin (b), serum C-peptide (c), and plasma glucagon (d) concentrations after administration of single oral
doses of sitagliptin 25 (white circles) or 200 mg (black triangles) or placebo (black circles) and an OGTT at 2 h postdose. Plasma glucose
concentrations are also displayed for the 2 h after a standardized meal at 6 h postdose and an OGTT at 24 h postdose. Data are expressed as
geometric mean±SE. [Reprinted with permission from The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 11 4612–4619,
Copyright 2006, The Endocrine Society]
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with those observed by vildagliptin, wherein a 4-week study
in subjects with mild T2D supported similar inhibition of
DPP4 activity in conjunction with reduced glucagon levels
and unaltered insulin levels (31). This suggested that acceler-
ation of the program based on ﬁrst principles elaborated
above was justiﬁed.
Early Clinical Development—Special Populations
(Obese Subjects)
The pharmacodynamics of sitagliptin after multiple dosing
was also assessed in obese subjects (36). Treatment with
sitagliptin 200 mg b.i.d. for 28 days led to near maximal inhibition
of plasma DPP4 activity (~90%, uncorrected). Therefore, DPP4
inhibition was sustained over a longer period of dosing.
Active GLP-1 levels increased, following an OGTT, by
approximately two- to three-fold as compared to placebo and
to pretreatment baseline active GLP-1 levels. Sitagliptin also
increased the ratio of active to total GLP-1 levels by a similar
degree. Treatment with sitagliptin also resulted in a statisti-
cally signiﬁcant reduction in post-OGTT glucose excursion on
both Days 14 and 28, as compared to placebo. There was no
weight gain observed after 28 days of treatment with
sitagliptin in obese individuals.
Accelerating Sitagliptin Early Development, the Returns
As described above, the interplay between proximal
target engagement biomarkers and distal disease related
biomarkers has been effectively delineated for sitagliptin,
both from a compound perspective as well as the mechanism
of action perspective. A positive proof-of-concept was
achieved since both target engagement and disease related
biomarkers were positive. This reduced the uncertainty in a
new mechanism for the treatment of T2D. The biomarker
strategy employed in the sitagliptin program made it amena-
ble to simple exposure/response relationships, which guided
early clinical drug development. In the case of the sitagliptin
program, it provided an opportunity to proceed to Phase IIB
dose range-ﬁnding studies following completion of the Phase
I program, bypassing a traditional Phase II study. This
approach was supported by the observed tolerability at
supra-therapeutic doses as high as 800-mg (single dose),
600-mg for 10 days or 400-mg for 28-days.
A PK/PD evaluation indicated that near maximal glucose
lowering following an OGTT occurs at approximately 100 nM
(corresponding to approximately 80% plasma DPP4 inhibi-
tion, uncorrected). In addition, near maximal increases (i.e.,
approximately two- to threefold) in the levels of active GLP-1
and intact GIP, as compared to placebo, were also reached at
plasma concentrations of 100 nM. These data suggested that
sustained plasma concentrations of 100 nM or greater over
the dosing interval would result in maximal or near maximal
efﬁcacy of sitagliptin in clinical practice. These observations
were also in general agreement with preclinical studies where
near maximal efﬁcacy was observed in animal models with
plasma DPP4 inhibition of 80%.
A trough concentration of approximately 100 nM (there-
by achieving 80% inhibition of DPP4 activity) was predicted
Fig. 5. Effect of sitagliptin (25, 50, 100, 200, 400, and 600 mg once daily and 300 mg twice daily) or placebo
on geometric mean of weighted average active GLP-1 concentrations through 2 h following standardized
meals at 4, 10, and 24 h postdose in healthy male subjects. [Reprinted from Clinical Therapeutics, 28(1),
Jan 2006, pages 55–72, copyright (2006), with permission from Excerpta Medica, Inc.]
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demonstrate that 100 mg once daily was near maximal with
respect to reductions in HbA1c. In addition, multiple twice
daily doses up to 50 mg twice daily were also tested to assess
the relative beneﬁts of maintaining higher plasma trough
concentrations of sitagliptin. Subsequently, studies evaluating
the efﬁcacy and safety and tolerability of 200 mg once daily
and 100 mg once daily were also incorporated in Phase III.
The average time taken for a new molecule to progress
from ﬁrst introduction to man to Phase III dose is approxi-
mately 3.5 years (48). For the sitagliptin program, the
biomarker strategy effectively employed in early development
enabled ﬁrst-in-man study to Phase III in as little as 2.1 years.
The reduced time to ﬁling was supported by a biomarker
strategy which was in alignment with a simple exposure/
response approach and increased the efﬁciency of drug
development.
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